5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Anti-Inflammatory Effect for Atherosclerosis Progression by Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitor in a Normoglycemic Rabbit Model

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background and Objectives

          We sought to investigate an anti-atherosclerotic and anti-inflammatory effect of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in normoglycemic atherosclerotic rabbit model.

          Methods

          Male New Zealand white rabbits (n=26) were fed with a 1% high-cholesterol diet for 7 weeks followed by normal diet for 2 weeks. After balloon catheter injury, the rabbits were administered with the Dapagliflozin (1mg/kg/day) or control-medium for 8 weeks (n=13 for each group). All lesions were assessed with angiography, optical coherence tomography (OCT), and histological assessment.

          Results

          Atheroma burden (38.51±3.16% vs. 21.91±1.22%, p<0.01) and lipid accumulation (18.90±3.63% vs. 10.20±2.03%, p=0.047) was significantly decreased by SGLT-2 inhibitor treatment. The SGLT-2 inhibitor group showed lower macrophage infiltration (20.23±1.89% vs. 12.72±1.95%, p=0.01) as well as tumor necrosis factor (TNF)-α expression (31.17±4.40% vs. 19.47±2.10%, p=0.025). Relative area of inducible nitric oxide synthase + macrophages was tended to be lower in the SGLT-2 inhibitor-treated group (1.00±0.16% vs. 0.71±0.10%, p=0.13), while relative proportion of Arg1 + macrophage was markedly increased (1.00±0.27% vs. 2.43±0.64%, p=0.04). As a result, progression of atherosclerosis was markedly attenuated in SGLT-2 inhibitor treated group (OCT area stenosis, 32.13±1.20% vs. 22.77±0.88%, p<0.01). Mechanistically, SGLT-2 treatment mitigated the inflammatory responses in macrophage. Especially, Toll-like receptor 4/nuclear factor-kappa B signaling pathway, and their downstream effectors such as interleukin-6 and TNF-α were markedly suppressed by SGLT-2 inhibitor treatment.

          Conclusions

          These results together suggest that SGLT-2 inhibitor exerts an anti-atherosclerotic effect through favorable modulation of inflammatory response as well as macrophage characteristics in non-diabetic situation.

          Related collections

          Most cited references19

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Understanding the Mysterious M2 Macrophage through Activation Markers and Effector Mechanisms

          The alternatively activated or M2 macrophages are immune cells with high phenotypic heterogeneity and are governing functions at the interface of immunity, tissue homeostasis, metabolism, and endocrine signaling. Today the M2 macrophages are identified based on the expression pattern of a set of M2 markers. These markers are transmembrane glycoproteins, scavenger receptors, enzymes, growth factors, hormones, cytokines, and cytokine receptors with diverse and often yet unexplored functions. This review discusses whether these M2 markers can be reliably used to identify M2 macrophages and define their functional subdivisions. Also, it provides an update on the novel signals of the tissue environment and the neuroendocrine system which shape the M2 activation. The possible evolutionary roots of the M2 macrophage functions are also discussed.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.

            Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin, dapagliflozin, and canagliflozin, are now widely approved antihyperglycemic therapies. Because of their unique glycosuric mechanism, SGLT2 inhibitors also reduce weight. Perhaps more important are the osmotic diuretic and natriuretic effects contributing to plasma volume contraction, and decreases in systolic and diastolic blood pressures by 4 to 6 and 1 to 2 mm Hg, respectively, which may underlie cardiovascular and kidney benefits. SGLT2 inhibition also is associated with an acute, dose-dependent reduction in estimated glomerular filtration rate by ≈5 mL·min(-1)·1.73 m(-2) and ≈30% to 40% reduction in albuminuria. These effects mirror preclinical observations suggesting that proximal tubular natriuresis activates renal tubuloglomerular feedback through increased macula densa sodium and chloride delivery, leading to afferent vasoconstriction. On the basis of reduced glomerular filtration, glycosuric and weight loss effects are attenuated in patients with chronic kidney disease (estimated glomerular filtration rate 30% reductions in cardiovascular mortality, overall mortality, and heart failure hospitalizations associated with empagliflozin, even though, by design, the hemoglobin A1c difference between the randomized groups was marginal. Aside from an increased risk of mycotic genital infections, empagliflozin-treated patients had fewer serious adverse events, including a lower risk of acute kidney injury. In light of the EMPA-REG OUTCOME results, some diabetes clinical practice guidelines now recommend that SGLT2 inhibitors with proven cardiovascular benefit be prioritized in patients with type 2 diabetes mellitus who have not achieved glycemic targets and who have prevalent atherosclerotic cardiovascular disease. With additional cardiorenal protection trials underway, sodium-related physiological effects of SGLT2 inhibitors and clinical correlates of natriuresis, such as the impact on blood pressure, heart failure, kidney protection, and mortality, will be a major management focus.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Atherosclerosis. the road ahead.

                Bookmark

                Author and article information

                Journal
                Korean Circ J
                Korean Circ J
                KCJ
                Korean Circulation Journal
                The Korean Society of Cardiology
                1738-5520
                1738-5555
                May 2020
                12 February 2020
                : 50
                : 5
                : 443-457
                Affiliations
                [1 ]Yonsei Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul, Korea.
                [2 ]Cardiology Division, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea.
                [3 ]Graduate Program in Science for Aging, Yonsei University, Seoul, Korea.
                [4 ]Cardiovascular Product Evaluation Center, Yonsei University College of Medicine, Seoul, Korea.
                [5 ]Division of Cardiology, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea.
                [6 ]Department of Cardiology, Ewha Womans University Seoul Hospital, Seoul, Korea.
                [7 ]Division of Cardiology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
                [8 ]Division of Endocrinology and Metabolism, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
                Author notes
                Correspondence to: Jung-Sun Kim, MD, PhD. Cardiology Division, Severance Cardiovascular Hospital, Yonsei University College of Medicine, 50-1, Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea. KJS1218@ 123456yuhs.ac

                *Seul-Gee Lee and Seung-Jun Lee contributed equally to this work.

                Author information
                https://orcid.org/0000-0002-9176-3075
                https://orcid.org/0000-0002-9201-4818
                https://orcid.org/0000-0002-4478-1772
                https://orcid.org/0000-0003-2263-3274
                https://orcid.org/0000-0001-7070-7720
                https://orcid.org/0000-0001-5226-7290
                https://orcid.org/0000-0003-3284-0904
                https://orcid.org/0000-0002-6219-4942
                https://orcid.org/0000-0002-4585-1488
                https://orcid.org/0000-0002-4949-8976
                https://orcid.org/0000-0002-5151-3653
                https://orcid.org/0000-0003-4893-039X
                https://orcid.org/0000-0002-7071-4370
                https://orcid.org/0000-0003-2493-066X
                https://orcid.org/0000-0001-7748-5788
                https://orcid.org/0000-0002-2009-9760
                https://orcid.org/0000-0002-2090-2031
                https://orcid.org/0000-0002-2169-3112
                Article
                10.4070/kcj.2019.0296
                7098824
                32153145
                9f31dbca-cafd-4b6c-b597-cf038004c648
                Copyright © 2020. The Korean Society of Cardiology

                This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 16 September 2019
                : 20 December 2019
                : 16 January 2020
                Funding
                Funded by: Korean Society of Cardiology;
                Award ID: 201601-01
                Funded by: Yonsei University College of Medicine, CrossRef https://doi.org/10.13039/501100008005;
                Award ID: 6-2016-0082
                Funded by: Ministry of Health and Welfare, CrossRef https://doi.org/10.13039/501100003625;
                Award ID: HI15C1277
                Funded by: Cardiovascular Research Center;
                Categories
                Original Article

                Cardiovascular Medicine
                atherosclerosis,sodium-glucose transporter-2,sodium-glucose transporter 2 inhibitors,macrophages

                Comments

                Comment on this article